Recently, JOINN Laboratories (China) Co., Ltd. (JOINN) appointed Dr. Yongbin Zhang, a former senior expert of the US FDA, as the Vice president (VP) and co-Chief Technology Officer (Co-CTO) of the company, to be fully responsible for the improvement of the company's non-clinical evaluation technology system and capability innovation.

As a senior toxicologist, Dr. Zhang has extensive experience in the management of new drug review and safety evaluation projects. During his 15-year FDA career, Dr. Zhang served as a non-clinical senior reviewer at the Center for New Drug Review (CDER/ OND) for the marketing approval of hundreds of INDs for new drug development and nearly ten new drugs (NDAs, BLAs, and Supplements). And participated in the drafting and formulation of a number of FDA new drug evaluation guidelines. Prior to joining CDER, he was a Principal Investigator at the National Center for Toxicology Research (NCTR), part of the FDA, where he established and led the FDA's NanoToxicology Laboratory and participated in several new drug and device related research and safety evaluations. Dr. Zhang graduated from China Agricultural University with a degree in Veterinary medicine, and later received a Ph.D. in Toxicology from Oklahoma State University, USA, and completed postdoctoral research at NCTR. Dr. Zhang has received the FDA Distinguished Young Scientist Award and the FDA Distinguished Service Award. He is enthusiastic about the public service of his profession, and has served as President of the North American Chinese Society of Toxicology (AACT), an affiliate of the American Society of Toxicology (SOT), and as a member of the NanoToxicology Professional Committee.
Dr. Zhang said, "It is my long-cherished wish to return to China and participate in the drug innovation." Dr. Zhang joined JOINN with full enthusiasm for struggle, and injected new impetus into the development of the company. Together with Dr. Dylan Yao (sVP, CSO) and many other senior review experts from the US FDA and China CDE who have joined JOINN, as well as the technical team of JOINN for nearly 30 years, we will provide a more solid talent and technical foundation for the accelerated transformation and internationalization of pharmaceutical innovation achievements, and will also more effectively guarantee the sustainable development of the company and the realization of strategic goals.
Those who know the changes will win, and those who keep the right will make progress. In the current complex and changing development state of the industry, JOINN will continue to recruit talents, innovative ability, pioneering, with high-quality and efficient drug evaluation services, support the transformation of pharmaceutical innovation technology, and accelerate the registration and listing process of innovative drugs in the world.